A certificate of analysis (COA) is a laboratory's report on one sample. Buyers often read it as a verdict on a product: that the vial holds the named peptide, in the labeled amount, free of contamination. A single report can support some of those conclusions and not others, depending on which tests it contains.
Four questions are worth separating before reading any numbers:
- Identity: is the main component the molecule named on the label?
- Purity: how much of what the method detected is that molecule?
- Content: how many milligrams of peptide does the vial hold?
- Contaminants: were endotoxin, sterility, heavy-metal or other safety tests run at all?
A report that answers one of these is not evidence about the others.
Start with the header, not the headline number
The top of the report says what was tested, by whom and when. Check it before any result:
- Laboratory: a named lab, with a way to contact it or look up the report.
- Date: when the sample was tested.
- Batch or lot number: it should match the number printed on the vial, not just the product name.
- Sample description: the compound and amount the lab says it received, which should match the product the report is attached to.
- Client: whether the vendor submitted the sample, or a buyer bought a retail vial and sent it in.
A report arranged by the seller is what drug regulation calls a supplier's report of analysis. Even licensed drug manufacturers may rely on one only if they run at least one specific identity test of their own and periodically validate the supplier's test results, under 21 CFR 211.84(d)(2). That rule does not govern research-use products, but its logic carries over: a seller's report is a claim, and an independent result is a check on it.
Purity: what the HPLC number measures
The headline figure, often 98% or 99%, usually comes from high-performance liquid chromatography (HPLC). The sample is pushed through a column that separates its components, and a UV detector, usually set around 210-220 nm where peptide bonds absorb, records each one as a peak. Purity is the main peak's area as a percentage of all the peak area the detector recorded.
That definition sets the limits of the number:
- It is a share of the detected signal, not a share of the powder's weight.
- It does not register water or counterions such as trifluoroacetate (TFA) or acetate, which make up part of the mass of a freeze-dried peptide.
- An impurity that leaves the column at the same time as the main peak is counted as the main peak. FDA's own laboratory has found deletion and insertion impurities that a drug applicant's HPLC methods could not separate from the peptide.
- It does not show that the main peak is the named peptide. That is the identity question.
If the chromatogram is attached, check that the method is stated (column, detection wavelength, gradient), that one peak clearly dominates, and that the table of integrated peaks lists the small peaks rather than leaving them out.
For scale, FDA's July 2026 draft guidance for generic semaglutide asks applicants to report each peptide-related impurity above 0.1% of the drug substance and to identify any above 0.5%. A research-market COA reporting 98.5% purity usually does not say what the other 1.5% is.
Identity: reading the mass spectrum
Mass spectrometry (MS) measures the mass of the molecules in a sample. A report should show an observed mass beside the expected mass of the named compound, and the two should agree closely. The expected figure can be checked against the compound's entry in PubChem.
Electrospray spectra usually show the same molecule several times, carrying different numbers of charges, so peaks appear at roughly a half, a third or a quarter of the molecular weight. That is normal. The report should say which peaks it assigned and what mass it calculated from them.
A matching mass is strong evidence of identity, with limits. A standard mass reading cannot tell apart molecules of identical mass, such as a peptide in which one amino acid has flipped to its mirror-image form during synthesis. Specialized methods can separate them, but a typical COA does not report them. And a mass match says nothing about how much peptide is present.
The sample line matters too. In July, CBS News reported that a certificate presented for retatrutide appeared to identify its sample as tirzepatide (our coverage). The compound the lab says it received should be the one on the label.
Content: how many milligrams are in the vial
Purity and content are separate measurements. A vial labeled 10 mg can hold a 99%-pure peptide and still contain less than 10 mg of it.
Two things drive the gap. The standard way of making and purifying synthetic peptides leaves them as salts, most often of TFA, and the powder also holds some water. The peptide itself is therefore less than 100% of the powder by weight. In one published analysis, a peptide carried 0.33 mg of TFA per milligram of salt while its HPLC purity stayed above 96%. Net peptide content is measured with a different method, such as amino acid analysis or a nitrogen-based method, with water and counterions determined separately. The second factor is fill: how much powder went into each vial.
Some third-party reports state a measured quantity per vial next to purity. A report that gives only a purity percentage cannot say whether the vial holds its labeled amount.
This is why price per milligram carries a caveat. PeptideScouter compares listings by the milligrams each vendor states. A low price per milligram describes the listing, not a measurement of the vial (see the methodology).
Endotoxin and sterility are separate tests
Bacterial endotoxins are components of the outer membrane of certain bacteria. Bacteria release them when they die, so a product can carry endotoxin with no live bacteria present. Endotoxin is measured with a limulus amebocyte lysate (LAL) test and reported in endotoxin units (EU). Sterility, meaning whether live microorganisms are present, is a separate test, and drug regulation treats sterile and pyrogen-free as separate requirements.
Neither is implied by a purity or identity result. A report without an endotoxin line has not tested for endotoxin.
Heavy metals: which elements, and against what limit
Some COAs add a heavy-metals line. It looks for elemental impurities, which can come from catalysts used in synthesis, contact with processing equipment, or containers. HPLC purity does not measure them.
The four elements regulators treat as most important are lead, cadmium, arsenic and mercury. The ICH Q3D guideline, which FDA has adopted, puts them in its top class as human toxicants with little or no use in drug manufacturing.
The older pharmacopeial "heavy metals" test was retired in 2018 in favor of limits for individual elements. Three things make a heavy-metals result readable:
- Named elements: a single "heavy metals" figure does not say which elements were measured.
- Units and detection limit: results are concentrations, usually in parts per million, and "not detected" is only as informative as the detection limit printed beside it.
- The limit used: regulatory limits start from a permitted daily exposure that varies by element and route, so a "pass" means little unless the report names the limit it was compared against.
Like endotoxin, a clean heavy-metals result says nothing about identity, purity or content.
Checking that a certificate is genuine
A convincing PDF is easy to produce. A few checks catch most problems:
- Confirm with the lab. Many labs let anyone look a report up by its number. If not, ask the lab directly.
- Match the lot. The batch number on the report should match the one on the vial.
- Look for reuse. One report attached to several products, sizes or batches is a warning sign.
- Check the dates. A report much older than the batch on sale probably describes a different sample.
- Read the sample line. The compound the lab received should be the one named on the label.
In the CBS case above, a manager at the laboratory named on the documents told CBS it had not issued them.
What a COA cannot tell you
Even a complete, genuine report covers only the sample tested. It does not establish that every vial in the lot matches, that the peptide stayed stable through shipping and storage, or that the next batch was made the same way.
A missing specification column is not a red flag in itself. A manufacturer's release COA compares each result against an acceptance limit. An independent test of a retail vial usually reports results without limits, because the buyer who commissioned it set none.
No certificate changes a product's regulatory status. Research-use-only peptides are not approved drugs, and a laboratory result on one sample does not substitute for the manufacturing controls an approval requires.
Sources
- 21 CFR 211.84, Testing and approval or rejection of components, eCFR: conditions for relying on a supplier's report of analysis.
- 21 CFR 211.167, Special testing requirements, eCFR: sterility and pyrogen-free as separate test requirements.
- FDA, draft product-specific guidance on semaglutide injection, July 2026: impurity reporting and identification thresholds for generic peptide applications.
- Zeng et al., "Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control," AAPS Journal, 2015: FDA laboratory findings on impurities that HPLC-UV methods did not resolve.
- Mant et al., "HPLC analysis and purification of peptides," Methods in Molecular Biology, 2007: UV detection of peptides at 210-220 nm.
- Sikora et al., "The Role of Counter-Ions in Peptides: An Overview," Pharmaceuticals, 2020: why synthetic peptides are isolated as TFA salts.
- Erckes et al., analysis and exchange of TFA as a counterion in synthetic peptides, Pharmaceuticals, 2025: measured TFA content alongside HPLC purity.
- Gomez-Guerrero et al., "Synthetic Peptides in Doping Control: A Powerful Tool for an Analytical Challenge," ACS Omega, 2022: peptide content, counterion and water as separate determinations.
- Jia et al., characterization of D-amino acid containing peptide epimers, Analytical Chemistry, 2014: why same-mass epimers challenge mass spectrometry.
- FDA, Pyrogen and Endotoxins Testing: Questions and Answers: endotoxin testing and limits in endotoxin units.
- ICH Q3D(R2) Elemental Impurities, FDA guidance for industry, September 2022: element classes, sources of elemental impurities and permitted daily exposures.
- FDA, Elemental Impurities in Drug Products, guidance for industry, August 2018: replacement of the USP heavy metals chapter by element-specific limits.
- FDA, Inspection Technical Guide: Bacterial Endotoxins/Pyrogens: endotoxin release from bacterial cells and the endotoxin unit.
- CBS News, "What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug," updated July 2, 2026: the mislabeled certificate and the laboratory's statement.
Regulatory documents checked September 25, 2026.